Interstitial Lung Diseases - Pipeline Insight, 2021
This report can be delivered to the clients within 2-3 Business Days
DelveInsight’s, “Interstitial Lung Diseases - Pipeline Insight, 2021,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Interstitial Lung Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Interstitial Lung Disease: Overview
Interstitial lung disease is a long-term (chronic) lung disease. It happens because of damage between the air sacs in the lung. The damage scars the lung and causes breathing problems. People with interstitial lung disease get breathless during exercise and may have a dry cough. These problems may get worse slowly or very quickly. The cause of interstitial lung disease is not known; however, a major contributing factor is thought to be inhaling environmental or occupational pollutants such as inorganic or organic dusts. People with interstitial lung disease usually go to the doctor because of shortness of breath or a cough. The doctor will probably use imaging tests of your lungs to find out the problem. Such tests include- Chest X-ray, Lung function test, CT scan, and lung biopsy.
'Interstitial Lung Disease - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Interstitial Lung Disease pipeline landscape is provided which includes the disease overview and Interstitial Lung Disease treatment guidelines. The assessment part of the report embraces, in depth Interstitial Lung Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Interstitial Lung Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Interstitial Lung Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Interstitial Lung Disease Emerging Drugs
Further product details are provided in the report……..
Interstitial Lung Disease: Therapeutic Assessment
This segment of the report provides insights about the different Interstitial Lung Disease drugs segregated based on following parameters that define the scope of the report, such as:
Interstitial Lung Disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Interstitial Lung Disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Interstitial Lung Disease drugs.
Interstitial Lung Disease Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Interstitial Lung Diseases - Pipeline Insight, 2021,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Interstitial Lung Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Interstitial Lung Disease: Overview
Interstitial lung disease is a long-term (chronic) lung disease. It happens because of damage between the air sacs in the lung. The damage scars the lung and causes breathing problems. People with interstitial lung disease get breathless during exercise and may have a dry cough. These problems may get worse slowly or very quickly. The cause of interstitial lung disease is not known; however, a major contributing factor is thought to be inhaling environmental or occupational pollutants such as inorganic or organic dusts. People with interstitial lung disease usually go to the doctor because of shortness of breath or a cough. The doctor will probably use imaging tests of your lungs to find out the problem. Such tests include- Chest X-ray, Lung function test, CT scan, and lung biopsy.
'Interstitial Lung Disease - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Interstitial Lung Disease pipeline landscape is provided which includes the disease overview and Interstitial Lung Disease treatment guidelines. The assessment part of the report embraces, in depth Interstitial Lung Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Interstitial Lung Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Interstitial Lung Disease R&D. The therapies under development are focused on novel approaches to treat/improve Interstitial Lung Disease.
This segment of the Interstitial Lung Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Interstitial Lung Disease Emerging Drugs
- AD-214: AdAlta
- Abatacept: Bristol-Myers Squibb
- ATYR1923: aTyr Pharma
Further product details are provided in the report……..
Interstitial Lung Disease: Therapeutic Assessment
This segment of the report provides insights about the different Interstitial Lung Disease drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Interstitial Lung Disease
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Interstitial Lung Disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Interstitial Lung Disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Interstitial Lung Disease drugs.
Interstitial Lung Disease Report Insights
- Interstitial Lung Disease Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Interstitial Lung Disease drugs?
- How many Interstitial Lung Disease drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Interstitial Lung Disease?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Interstitial Lung Disease therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Interstitial Lung Disease and their status?
- What are the key designations that have been granted to the emerging drugs?
- AdAlta
- Bristol-Myers Squibb
- aTyr Pharma
- Avalyn Pharmaceuticals
- Beijing Continent Pharmaceutical
- Regend Therapeutics
- Reata Pharmaceuticals
- FibroGen
- PureTech Health
- Bellerophon Pulse Technologies
- OncoArendi Therapeutics
- LTT Bio-Pharma
- EmphyCorp
- Genentech
- Blade Therapeutics
- Acceleron Pharma
- AD-214
- Abatacept
- ATYR1923
- Pirfenidone inhalation
- RO-0220912
- Lung stem cells
- Bardoxolone methyl
- Pamrevlumab
- Deupirfenidone
- INOpulse
- OATD 01
- LT 0011
- GDC 3280
- BLD 2660
- ACE 1334
Introduction
Executive Summary
Interstitial Lung Disease: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Preregistration)
Comparative Analysis
Pirfenidone: Beijing Continent Pharmaceutical Co, Ltd.
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Abatacept: Bristol-Myers Squibb
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
AD-214 : AdAlta
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Interstitial Lung Disease Key Companies
Interstitial Lung Disease Key Products
Interstitial Lung Disease- Unmet Needs
Interstitial Lung Disease- Market Drivers and Barriers
Interstitial Lung Disease- Future Perspectives and Conclusion
Interstitial Lung Disease Analyst Views
Interstitial Lung Disease Key Companies
Appendix
Executive Summary
Interstitial Lung Disease: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Preregistration)
Comparative Analysis
Pirfenidone: Beijing Continent Pharmaceutical Co, Ltd.
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Abatacept: Bristol-Myers Squibb
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
AD-214 : AdAlta
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Interstitial Lung Disease Key Companies
Interstitial Lung Disease Key Products
Interstitial Lung Disease- Unmet Needs
Interstitial Lung Disease- Market Drivers and Barriers
Interstitial Lung Disease- Future Perspectives and Conclusion
Interstitial Lung Disease Analyst Views
Interstitial Lung Disease Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Interstitial Lung Disease
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Interstitial Lung Disease
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Interstitial Lung Disease
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Interstitial Lung Disease
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
